|
1
|
Leron E, Weintraub AY, Mastrolia SA and
Schwarzman P: Overactive bladder syndrome: Evaluation and
management. Curr Urol. 11:117–125. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Abrams P, Kelleher CJ, Kerr LA and Rogers
RG: Overactive bladder significantly affects quality of life. Am J
Manag Care. 6 (Suppl):S580–S590. 2000.PubMed/NCBI
|
|
3
|
Milsom I, Abrams P, Cardozo L, Roberts RG,
Thüroff J and Wein AJ: How widespread are the symptoms of an
overactive bladder and how are they managed? A population-based
prevalence study. BJU Int. 87:760–766. 2001.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Coyne KS, Sexton CC, Kopp ZS, Ebel-Bitoun
C, Milsom I and Chapple C: The impact of overactive bladder on
mental health, work productivity and health-related quality of life
in the UK and Sweden: Results from EpiLUTS. BJU Int. 108:1459–1471.
2011.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Donaldson MM, Thompson JR, Matthews RJ,
Dallosso HM and McGrother CW: Leicestershire MRC Incontinence Study
Group. The natural history of overactive bladder and stress urinary
incontinence in older women in the community: A 3-year prospective
cohort study. Neurourol Urodyn. 25:709–716. 2006.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Lightner DJ, Gomelsky A, Souter L and
Vasavada SP: Diagnosis and treatment of overactive bladder
(non-neurogenic) in adults: AUA/SUFU Guideline amendment 2019. J
Urol. 202:558–563. 2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Stewart WF, Van Rooyen JB, Cundiff GW,
Abrams P, Herzog AR, Corey R, Hunt TL and Wein AJ: Prevalence and
burden of overactive bladder in the United States. World J Urol.
20:327–336. 2003.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Abrams P, Blaivas JG, Stanton SL and
Andersen JT: The standardisation of terminology of lower urinary
tract function The International Continence Society Committee on
Standardisation of Terminology. Scand J Urol Nephrol Suppl.
114:5–19. 1988.PubMed/NCBI
|
|
9
|
Drake MJ: Do we need a new definition of
the overactive bladder syndrome? ICI-RS 2013. Neurourol Urodyn.
33:622–624. 2014.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Van Dijk MM, Wijkstra H, Debruyne FM, De
La Rosette JJ and Michel MC: The role of nocturia in the quality of
life of men with lower urinary tract symptoms. BJU Int.
105:1141–1146. 2010.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Cerruto MA, Asimakopoulos AD, Artibani W,
Del Popolo G, La Martina M, Carone R and Finazzi-Agrò E: Insight
into new potential targets for the treatment of overactive bladder
and detrusor overactivity. Urol Int. 89:1–8. 2012.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Robinson D and Cardozo L: Managing
overactive bladder. Climacteric. 22:250–256. 2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Burkhard FC, Bosch JLHR, Cruz F, Lemack
GE, Nambiar AK, Thiruchelvam N, Tubaro A, Ambühl D, Bedretdinova
DA, Farag F, et al: Urinary Incontinence in Adults. EAU Guidelines.
Edn. presented at the EAU Annual Congress Amsterdam, 2020.
https://uroweb.org/guideline/urinary-incontinence/.
Access date: March 21, 2021.
|
|
14
|
Abboudi H, Fynes MM and Doumouchtsis SK:
Contemporary therapy for the overactive bladder. Obstet Gynaecol.
13:98–106. 2011.
|
|
15
|
Willis-Gray MG, Dieter AA and Geller EJ:
Evaluation and management of overactive bladder: Strategies for
optimizing care. Res Rep Urol. 8:113–122. 2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Milsom I, Kaplan SA, Coyne KS, Sexton CC
and Kopp ZS: Effect of bothersome overactive bladder symptoms on
health-related quality of life, anxiety, depression, and treatment
seeking in the United States: Results from EpiLUTS. Urology.
80:90–96. 2012.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Irwin DE, Mungapen L, Milsom I, Kopp Z,
Reeves P and Kelleher C: The economic impact of overactive bladder
syndrome in six Western countries. BJU Int. 103:202–209.
2009.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Osman NI and Chapple CR: The management of
overactive bladder syndrome: A review of the European Association
of Urology Guidelines. Clin Pract. 10:593–606. 2013.
|
|
19
|
Hu TW and Wagner TH: Health-related
consequences of overactive bladder: An economic perspective. BJU
Int. 96 (Suppl 1):S43–S45. 2005.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Sexton CC, Coyne KS, Vats V, Kopp ZS,
Irwin DE and Wagner TH: Impact of overactive bladder on work
productivity in the United States: Results from EpiLUTS. Am J Manag
Care. 15 (Suppl 4):S98–S107. 2009.PubMed/NCBI
|
|
21
|
Onukwugha E, Zuckerman IH, McNally D,
Coyne KS, Vats V and Mullins CD: The total economic burden of
overactive bladder in the United States: A disease-specific
approach. Am J Manag Care. 15 (Suppl 4):S90–S97. 2009.PubMed/NCBI
|
|
22
|
Peyronnet B, Mironska E, Chapple C,
Cardozo L, Oelke M, Dmochowski R, Amarenco G, Gamé X, Kirby R, Van
Der Aa F and Cornu JN: A comprehensive review of overactive bladder
pathophysiology: On the way to tailored treatment. Eur Urol.
75:988–1000. 2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Robinson D, Cardozo L, Milsom I, Pons ME,
Kirby M, Koelbl H and Vierhout M: Oestrogens and overactive
bladder. Neurourol Urodyn. 33:1086–1091. 2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
de Boer TA, Salvatore S, Cardozo L,
Chapple C, Kelleher C, van Kerrebroeck P, Kirby MG, Koelbl H,
Espuna-Pons M, Milsom I, et al: Pelvic organ prolapse and
overactive bladder. Neurourol Urodyn. 29:30–39. 2010.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Bunn F, Kirby M, Pinkney E, Cardozo L,
Chapple C, Chester K, Cruz F, Haab F, Kelleher C, Milsom I, et al:
Is there a link between overactive bladder and the metabolic
syndrome in women? A systematic review of observational studies.
Int J Clin Pract. 69:199–217. 2015.PubMed/NCBI View Article : Google Scholar
|
|
26
|
de Boer TA, Slieker-ten Hove MC, Burger CW
and Vierhout ME: The prevalence and risk factors of overactive
bladder symptoms and its relation to pelvic organ prolapse symptoms
in a general female population. Int Urogynecol J. 22:569–575.
2011.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Vrijens D, Drossaerts J, van Koeveringe G,
Van Kerrebroeck P, van Os J and Leue C: Affective symptoms and the
overactive bladder-a systematic review. J Psychosom Res. 78:95–108.
2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Matsumoto S, Hashizume K, Wada N, Hori J,
Tamaki G, Kita M, Iwata T and Kakizaki H: Relationship between
overactive bladder and irritable bowel syndrome: A large-scale
internet survey in Japan using the overactive bladder symptom score
and Rome III criteria. BJU Int. 111:647–652. 2013.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Coyne KS, Sexton CC, Bell JA, Thompson CL,
Dmochowski R, Bavendam T, Chen CI and Quentin Clemens J: The
prevalence of lower urinary tract symptoms (LUTS) and overactive
bladder (OAB) by racial/ethnic group and age: Results from
OAB-POLL. Neurourol Urodyn. 32:230–237. 2013.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Gleason JL, Richter HE, Redden DT, Goode
PS, Burgio KL and Markland AD: Caffeine and urinary incontinence in
US women. Int Urogynecol J. 24:295–302. 2013.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Abrams P, Cardozo L, Fall M, Griffiths D,
Rosier P, Ulmsten U, van Kerrebroeck P, Victor A and Wein A:
Standardisation Sub-committee of the International Continence
Society. The standardisation of terminology of lower urinary tract
function: Report from the standardisation Sub-committee of the
International Continence Society. Neurourol Urodyn. 21:167–178.
2002.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Wein AJ and Rackley RR: Overactive
bladder: A better understanding of pathophysiology, diagnosis and
management. J Urol. 175:S5–S10. 2006.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Foon R and Toozs-Hobson P: Detrusor
overactivity. Obstetrics, Gynaecol Reprod Med. 17:255–260.
2007.
|
|
34
|
Brading AF: Spontaneous activity of lower
urinary tract smooth muscles: Correlation between ion channels and
tissue function. J Physiol. 570:13–22. 2006.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Chapple C: Chapter 2: Pathophysiology of
neurogenic detrusor overactivity and the symptom complex of
‘overactive bladder’. Neurourol Urodyn. 33 (Suppl 3):S6–S13.
2014.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Lee SR, Kim HJ, Kim A and Kim JH:
Overactive bladder is not only overactive but also hypersensitive.
Urology. 75:1053–1059. 2010.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Hubeaux K, Deffieux X, Desseaux K,
Verollet D, Damphousse M and Amarenco G: Stand up urgency: Is this
symptom related to a urethral mechanism? Prog Urol. 22:475–481.
2012.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Apostolidis A, Wagg A, Rahnam A'i MS,
Panicker JN, Vrijens D and von Gontard A: Is there ‘brain OAB’ and
how can we recognize it? International Consultation on
Incontinence-Research Society (ICI-RS) 2017. Neurourol Urodyn. 37
(Suppl 4):S38–S45. 2018.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Faraj K, Doo F, Boura J, Vereecke A and
Chancellor MB: A cross-sectional study in the USA of the
epidemiology and quality of life of underactive bladder symptoms.
Int Urol Nephrol. 48:1797–1802. 2016.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Malone-Lee JG and Al-Buheissi S: Does
urodynamic verification of overactive bladder determine treatment
success? Results from a randomized placebo-controlled study. BJU
Int. 103:931–937. 2009.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Imamura M, Williams K, Wells M and
McGrother C: Lifestyle interventions for the treatment of urinary
incontinence in adults. Cochrane Database Syst Rev.
2(CD003505)2015.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Kincade JE, Dougherty MC, Carlson JR,
Hunter GS and Busby-Whitehead J: Randomized clinical trial of
efficacy of self-monitoring techniques to treat urinary
incontinence in women. Neurourol Urodyn. 26:507–511.
2007.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Ostaszkiewicz J, Johnston L and Roe B:
Timed voiding for the management of urinary incontinence in adults.
Cochrane Database Syst Rev. 2004(CD002802)2004.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Wallace SA, Roe B, Williams K and Palmer
M: Bladder training for urinary incontinence in adults. Cochrane
Database Syst Rev. 2004(CD001308)2004.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Shafik A and Shafik IA: Overactive bladder
inhibition in response to pelvic floor muscle exercises. World J
Urol. 20:374–377. 2003.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Bø K, Kvarstein B and Nygaard I: Lower
urinary tract symptoms and pelvic floor muscle exercise adherence
after 15 years. Obstet Gynecol. 105:999–1005. 2005.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Abrams P, Andersson KE, Buccafusco JJ,
Chapple C, de Groat WC, Fryer AD, Kay G, Laties A, Nathanson NM,
Pasricha PJ and Wein AJ: Muscarinic receptors: Their distribution
and function in body systems, and the implications for treating
overactive bladder. Br J Pharmacol. 148:565–578. 2006.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Biastre K and Burnakis T: Trospium
chloride treatment of overactive bladder. Ann Pharmacother.
43:283–295. 2009.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Chapple CR, Khullar V, Gabriel Z, Muston
D, Bitoun CE and Weinstein D: The effects of antimuscarinic
treatments in overactive bladder: An update of a systematic review
and meta-analysis. Eur Urol. 54:543–562. 2008.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Novara G, Galfano A, Secco S, D'Elia C,
Cavalleri S, Ficarra V and Artibani W: A systematic review and
meta-analysis of randomized controlled trials with antimuscarinic
drugs for overactive bladder. Eur Urol. 54:740–763. 2008.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Shamliyan T, Wyman JF, Ramakrishnan R,
Sainfort F and Kane RL: Benefits and harms of pharmacologic
treatment for urinary incontinence in women: A systematic review.
Ann Intern Med. 156:861–874, W301-10. 2012.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Peeker R, Samsioe G, Kowalski J, Andersson
AS and Bergqvist A: A prospective observational study of the
effects of treatment with extended-release tolterodine on
health-related quality of life of patients suffering overactive
bladder syndrome in Sweden. Scand J Urol Nephrol. 44:138–146.
2010.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Sexton CC, Notte SM, Maroulis C,
Dmochowski RR, Cardozo L, Subramanian D and Coyne KS: Persistence
and adherence in the treatment of overactive bladder syndrome with
anticholinergic therapy: A systematic review of the literature. Int
J Clin Pract. 65:567–585. 2011.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Robinson D and Cardozo L: Antimuscarinic
drugs to treat overactive bladder. BMJ. 344(e2130)2012.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Nitti VW, Dmochowski R, Herschorn S, Sand
P, Thompson C, Nardo C, Yan X and Haag-Molkenteller C: EMBARK Study
Group. OnabotulinumtoxinA for the treatment of patients with
overactive bladder and urinary incontinence: Results of a phase 3,
randomized, placebo controlled trial. J Urol. 189:2186–2193.
2013.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Khullar V, Amarenco G, Angulo JC,
Cambronero J, Høye K, Milsom I, Radziszewski P, Rechberger T,
Boerrigter P, Drogendijk T, et al: Efficacy and tolerability of
mirabegron, a β(3)-adrenoceptor agonist, in patients with
overactive bladder: Results from a randomised European-Australian
phase 3 trial. Eur Urol. 63:283–295. 2013.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Maman K, Aballea S, Nazir J, Desroziers K,
Neine ME, Siddiqui E, Odeyemi I and Hakimi Z: Comparative efficacy
and safety of medical treatments for the management of overactive
bladder: A systematic literature review and mixed treatment
comparison. Eur Urol. 65:755–765. 2014.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Rosa GM, Ferrero S, Nitti VW, Wagg A,
Saleem T and Chapple CR: Cardiovascular safety of β3-adrenoceptor
agonists for the treatment of patients with overactive bladder
syndrome. Eur Urol. 9:311–323. 2016.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Wagg A, Franks B, Ramos B and Berner T:
Persistence and adherence with the new beta-3 receptor agonist,
mirabegron, versus antimuscarinics in overactive bladder: Early
experience in Canada. Can Urol Assoc J. 9:343–350. 2015.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Abrams P, Kelleher C, Staskin D,
Rechberger T, Kay R, Martina R, Newgreen D, Paireddy A, van Maanen
R and Ridder A: Combination treatment with mirabegron and
solifenacin in patients with overactive bladder: Efficacy and
safety results from a randomised, double-blind, dose-ranging, phase
2 study (Symphony). Eur Urol. 67:577–588. 2015.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Mangera A, Andersson KE, Apostolidis A,
Chapple C, Dasgupta P, Giannantoni A, Gravas S and Madersbacher S:
Contemporary management of lower urinary tract disease with
botulinum toxin A: A systematic review of botox
(onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol.
60:784–795. 2011.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Dmochowski R, Chapple C, Nitti VW,
Chancellor M, Everaert K, Thompson C, Daniell G, Zhou J and
Haag-Molkenteller C: Efficacy and safety of onabotulinumtoxinA for
idiopathic overactive bladder: A double-blind, placebo controlled,
randomized, dose ranging trial. J Urol. 184:2416–2422.
2010.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Apostolidis A, Dasgupta P, Denys P, Elneil
S, Fowler CJ, Giannantoni A, Karsenty G, Schulte-Baukloh H, Schurch
B and Wyndaele JJ: European Consensus Panel. Recommendations on the
use of botulinum toxin in the treatment of lower urinary tract
disorders and pelvic floor dysfunctions: A European consensus
report. Eur Urol. 55:100–119. 2009.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Mascarenhas F, Cocuzza M, Gomes CM and
Leão N: Trigonal injection of botulinum toxin-A does not cause
vesicoureteral reflux in neurogenic patients. Neurourol Urodyn.
27:311–314. 2008.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Dowson C, Watkins J, Khan MS, Dasgupta P
and Sahai A: Repeated botulinum toxin type A injections for
refractory overactive bladder: Medium-term outcomes, safety
profile, and discontinuation rates. Eur Urol. 61:834–839.
2012.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Ridout AE and Yoong W: Tibial nerve
stimulation for overactive bladder syndrome unresponsive to medical
therapy. J Obstet Gynaecol. 30:111–114. 2010.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Kabay SC, Kabay S, Yucel M and Ozden H:
Acute urodynamic effects of percutaneous posterior tibial nerve
stimulation on neurogenic detrusor overactivity in patients with
Parkinson's disease. Neurourol Urodyn. 28:62–67. 2009.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Govier FE, Litwiller S, Nitti V, Kreder KJ
Jr and Rosenblatt P: Percutaneous afferent neuromodulation for the
refractory overactive bladder: Results of a multicenter study. J
Urol. 165:1193–1198. 2001.PubMed/NCBI
|
|
69
|
MacDiarmid SA, Peters KM, Shobeiri SA,
Wooldridge LS, Rovner ES, Leong FC, Siegel SW, Tate SB and Feagins
BA: Long-term durability of percutaneous tibial nerve stimulation
for the treatment of overactive bladder. J Urol. 183:234–240.
2010.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Price N, Dawood R and Jackson SR: Pelvic
floor exercise for urinary incontinence: A systematic literature
review. Maturitas. 67:309–315. 2010.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Janknegt RA, Hassouna MM, Siegel SW,
Schmidt RA, Gajewski JB, Rivas DA, Elhilali MM, Milam DC, van
Kerrebroeck PE, Dijkema HE, et al: Long-term effectiveness of
sacral nerve stimulation for refractory urge incontinence. Eur
Urol. 39:101–106. 2001.PubMed/NCBI View Article : Google Scholar
|
|
72
|
van Kerrebroeck PE, van Voskuilen AC,
Heesakkers JP, Lycklama á Nijholt AA, Siegel S, Jonas U, Fowler CJ,
Fall M, Gajewski JB, Hassouna MM, et al: Results of sacral
neuromodulation therapy for urinary voiding dysfunction: Outcomes
of a prospective, worldwide clinical study. J Urol. 178:2029–2034.
2007.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Pathak AS and Aboseif SR: Overactive
bladder: Drug therapy versus nerve stimulation. Nat Clin Pract
Urol. 2:310–311. 2005.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Somani BK, Kumar V, Wong S, Pickard R,
Ramsay C, Nabi G, Grant A and N'Dow J: ABACUS Research Group. Bowel
dysfunction after transposition of intestinal segments into the
urinary tract: 8-year prospective cohort study. J Urol.
177:1793–1798. 2007.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Epstein BJ, Gums JG and Molina E: Newer
agents for the management of overactive bladder. Am Fam Physician.
74:2061–2068. 2006.PubMed/NCBI
|
|
76
|
Silva C, Silva J, Ribeiro MJ, Avelino A
and Cruz F: Urodynamic effect of intravesical resiniferatoxin in
patients with neurogenic detrusor overactivity of spinal origin:
Results of a double-blind randomized placebo-controlled trial. Eur
Urol. 48:650–655. 2005.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Lewis JM and Cheng EY: Non-traditional
management of the neurogenic bladder: Tissue engineering and
neuromodulation. ScientificWorldJournal. 7:1230–1241.
2007.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Chancellor MB and Hasenau DL: Is
behavioral therapy plus antimuscarinic better than drug alone to
treat overactive bladder? Rev Urol. 10:306–308. 2008.PubMed/NCBI
|
|
79
|
Dan Spinu A, Gabriel Bratu O, Cristina
Diaconu C, Maria Alexandra Stanescu A, Bungau S, Fratila O,
Bohiltea R and Liviu Dorel Mischianu D: Botulinum toxin in low
urinary tract disorders - over 30 years of practice (Review). Exp
Ther Med. 20:117–120. 2020.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Scarneciu I, Bungau S, Lupu AM, Scarneciu
CC, Bratu OG, Martha O, Tit DM, Aleya L and Lupu S: Efficacy of
instillation treatment with hyaluronic acid in relieving symptoms
in patients with BPS/IC and uncomplicated recurrent urinary tract
infections-Long-term results of a multicenter study. Eur J Pharm
Sci. 139(105067)2019.PubMed/NCBI View Article : Google Scholar
|
